1[1]Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res, 2001, 482(1-2):11
2[2]Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P450 3A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol, 1996, 49:311
3[3]Felix CA, Walker AH, Lange BJ et al. Association of CYP 3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA, 1998, 95:13 176
4[4]Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of genetic basis of polymorphic CYP3A5 expression. Nat Genet, 2001,27(4):383
5[5]Ariyoshi N, Sawamura Y, Kamataki T. A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem Biophys Res Commun. 2001, 281(3):810
6[6]Masimirembwa C, Persson I, Bertilsson L et al. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol, 1996, 42:713
7[7]Rao Y, Hoffmann E, Zia M et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol, 2000, 58:747
8[8]Adagu IS, Warhurst DC. Allele-specific, nested, one tube PCR: application to Pfmdr1 polymorphisms in Plasmodium falciparum. Parasitology, 1999, 119:1
9[9]Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther, 2001, 70(2):189
10[10]Bernal ML, Sinues B, Fanlo A et al. Frequency distribution of C3435T mutation in Exon 26 of the MDR1 gene in a Spanish population. Ther Drug Monit, 2003, 25(1):107
同被引文献11
1Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat Res 1999;436:227-261.
2Mohrenweiser HW, Jones IM. Variation in DNA repair is a factor in cancer susceptibility:a paradigm for the promises and perils of individual and population risk estimation? Mutat Res 1998;400:15-24.
3Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-318.
4Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA, Rebbeck TR. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998;95:13176-13181.
5Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391.
6Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant MDR1 alleles among european americans and african americans. Clin Pharmacol Ther 2001;70:189-199.
7Ross D, Traver RD, Siegel D, Kuehl BL, Misra V, Rauth AM. A polymorphism in NAD(P)H: quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer 1996;74:995-996.
8Lin P, Wang HJ, Lee H, Lee HS, Wang SL, Hsueh YM, Tsai KJ, Chen CY. NAD(P)H:quinone oxidoreductase polymorphism and lung cancer in Taiwan. J Toxicol Environ Health A 1999;58:187-197.
9Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, McLeod H. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol 2002;21:1119-1124.
